Valdecoxib: the rise and fall of a COX-2 inhibitor
Authors:
- 22 March 2013
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 14 (8) , 1077-1086
Abstract
(2013). Valdecoxib: the rise and fall of a COX-2 inhibitor. Expert Opinion on Pharmacotherapy: Vol. 14, No. 8, pp. 1077-1086.Keywords
This publication has 69 references indexed in Scilit:
- Pharmacodynamic of cyclooxygenase inhibitors in humansProstaglandins & Other Lipid Mediators, 2007
- Celecoxib for the Prevention of Colorectal Adenomatous PolypsNew England Journal of Medicine, 2006
- Celecoxib for the Prevention of Sporadic Colorectal AdenomasNew England Journal of Medicine, 2006
- Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trialsBMJ, 2006
- De Novo Synthesis of Cyclooxygenase-1 Counteracts the Suppression of Platelet Thromboxane Biosynthesis by AspirinCirculation Research, 2006
- Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunitiesJournal of Clinical Investigation, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryNew England Journal of Medicine, 2005
- ValdecoxibDrugs, 2002
- A Pharmacokinetic Study of Intramuscular (IM) Parecoxib Sodium in Normal SubjectsThe Journal of Clinical Pharmacology, 2001
- Elevated plasma fibrinopeptide A and thromboxane B2 levels during cardiopulmonary bypass.Circulation, 1980